Zobrazeno 1 - 10
of 162
pro vyhledávání: '"Prasad S. Kulkarni"'
Autor:
Prasad S. Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, Ashish Bavdekar, Madhu Gupta, Praveen Kulkarni, B.S. Garg, Nithya J. Gogtay, Muralidhar Tambe, Sanjay Lalwani, Kiranjit Singh, Renuka Munshi, Sushant Meshram, T.S. Selvavinayagam, Krishna Pandey, Devi Madhavi Bhimarasetty, S.R. Ramakrishnan, Chetanraj Bhamare, Abhijeet Dharmadhikari, Chandrashekhar Budhawant, Cyrille J. Bonhomme, Madhuri Thakar, Swarali N. Kurle, Elizabeth J. Kelly, Manish Gautam, Nivedita Gupta, Samiran Panda, Balram Bhargava, Cyrus S. Poonawalla, Umesh Shaligram, Dhananjay Kapse, Bhagwat Gunale
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
ABSTRACTAZD1222 (ChAdOx1 nCoV-19) is a replication-deficient adenoviral vectored coronavirus disease-19 (COVID-19) vaccine that is manufactured as SII-ChAdOx1 nCoV-19 by the Serum Institute of India Pvt Ltd following technology transfer from Oxford U
Externí odkaz:
https://doaj.org/article/8b89a3e8f8ac470894c80a7c06493aa6
Autor:
Prasad S. Kulkarni, Bhagwat Gunale, Sunil Kohli, Sanjay Lalwani, Srikanth Tripathy, Sonali Kar, Sidram Raut, Praveen Kulkarni, Aditi Apte, Ashish Bavdekar, Hira Lal Bhalla, Joyce S. Plested, Shane Cloney-Clark, MingZhu Zhu, Raj Kalkeri, Melinda Pryor, Stephanie Hamilton, Madhuri Thakar, Ranga S. Sannidhi, Punjita Baranwal, Chetanraj Bhamare, Abhijeet Dharmadhikari, Manish Gupta, Cyrus S. Poonawalla, Umesh Shaligram, Dhananjay Kapse, COVOVAX-Booster Study Group
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-14 (2023)
Abstract Due to waning immunity following primary immunization with COVID-19 vaccines, booster doses may be required. The present study assessed a heterologous booster of SII-NVX-CoV2373 (spike protein vaccine) in adults primed with viral vector and
Externí odkaz:
https://doaj.org/article/9a552b8a78384202b575842720c27791
Autor:
Gagandeep Kang, Anand Lakhkar, Chetanraj Bhamare, Abhijeet Dharmadhikari, Jyoti Narwadkar, Arti Kanujia, Sajjad Desai, Bhagwat Gunale, Cyrus S. Poonawalla, Prasad S. Kulkarni
Publikováno v:
Vaccine: X, Vol 15, Iss , Pp 100362- (2023)
Background: ROTASIIL, an oral live attenuated bovine-human reassortant pentavalent rotavirus vaccine, was approved in 2017. This post-marketing surveillance (PMS) was conducted to collect real-world data on the safety of ROTASIIL in India. Methods: O
Externí odkaz:
https://doaj.org/article/68d73e768154412791e8f4285eecd9e7
Autor:
Sajjad Desai, K. Anil, Anirudha Vyankatesh Potey, Y. Sindhu, Silvia Grappi, Giulia Lapini, Satyaprasad Manney, Parikshit Tyagi, Emanuele Montomoli, Cyrus S. Poonawalla, Prasad S. Kulkarni
Publikováno v:
npj Vaccines, Vol 7, Iss 1, Pp 1-6 (2022)
Abstract Yellow fever, a mosquito-borne flavivirus infection, is an important public health problem in Africa and Latin America. A Yellow Fever vaccine (YFV) was developed and tested in a study in India. This was a Phase I, open-label, randomized, co
Externí odkaz:
https://doaj.org/article/71efdbde43384da99e64a1d94508dcea
Autor:
Gagandeep Kang, Anand Lakhkar, Chetanraj Bhamare, Abhijeet Dharmadhikari, Jyoti Narwadkar, Arti Kanujia, Dhananjay Kapse, Bhagwat Gunale, Cyrus S. Poonawalla, Prasad S. Kulkarni
Publikováno v:
The Lancet Regional Health - Southeast Asia, Vol 14, Iss , Pp 100207- (2023)
Summary: Background: A vero cell-based inactivated Rabies Vaccine (Rabivax-S) and Rabies Human Monoclonal Antibody (Rabishield) have been approved since 2016. A post-marketing surveillance was conducted in India from 2020 to 2021 to gather real world
Externí odkaz:
https://doaj.org/article/b9f54205b1424c39b6a29ce58950f316
Autor:
Prasad S. Kulkarni, Abhijit Kadam, Sheela Godbole, Varsha Bhatt, Abhishek Raut, Sunil Kohli, Santanu Tripathi, Praveen Kulkarni, Rakhi Ludam, Madhav Prabhu, Ashish Bavdekar, Nithya J. Gogtay, Sushant Meshram, Tamilarasu Kadhiravan, Sonali Kar, D.H. Ashwath Narayana, Clarence Samuel, Govind Kulkarni, Abhay Gaidhane, Dipu Sathyapalan, Sidram Raut, Vijay Hadda, Hira Lal Bhalla, Chetanraj Bhamare, Abhijeet Dharmadhikari, Joyce S. Plested, Shane Cloney-Clarke, Mingzhu Zhu, Melinda Pryor, Stephanie Hamilton, Madhuri Thakar, Ashwini Shete, Manish Gautam, Nivedita Gupta, Samiran Panda, Umesh Shaligram, Cyrus S. Poonawalla, Balram Bhargava, Bhagwat Gunale, Dhananjay Kapse, Shubhangi A. Kanitkar, Arjun L. Kakrani, Srikanth P. Tripathy, Abhijit V. Tilak, Akshay A. Dhamne, Shahzad Beg Mirza, Prachi V. Athavale, Mandakini Bhowmik, Parag J. Ratnakar, Subodh Gupta, Vijayshri Deotale, Jyoti Jain, Ashwini Kalantri, Vineet Jain, Nidhi Goyal, Alok Arya, Temsunaro Rongsen-Chandola, Shreyasi Dasgupta, Pratibha Periera, Vanmathi A, Anand Kawade, Arunkumar Gondhali, Palvi Kudyar, Abhishek Singh, Ravi Yadav, Alina Alexander, Venugopalan Gunasekaran, Sekar Dineshbabu, P.C. Samantaray, H.S. Ravish, Deepshikha Kamra, Shilpa Gaidhane, Quazi Syed Zahiruddin, Merlin Moni, Anil Kumar, Ameet Dravid, Anant Mohan, Tejas Suri, Tejas K. Patel, Surekha Kishore, Rahul Choche, Deepak Ghatage, Sugam Salvi
Publikováno v:
The Lancet Regional Health - Southeast Asia, Vol 10, Iss , Pp 100139- (2023)
Summary: Background: NVX-CoV2373, a Covid-19 vaccine was developed in the USA with ∼90% efficacy. The same vaccine is manufactured in India after technology transfer (called as SII-NVX-CoV2373), was evaluated in this phase 2/3 immuno-bridging study
Externí odkaz:
https://doaj.org/article/82d9dafd89e042aabbf3940c237b71b1
Autor:
Nilesh Gujar, Muralidhar Tambe, Malangori Parande, Nandkumar Salunke, Ganesh Jagdale, Sarah G. Anderson, Abhijeet Dharmadhikari, Anand Lakhkar, Prasad S. Kulkarni
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 10, Pp 3316-3321 (2021)
Currently, most licensed vaccines against SARS-CoV-2 infection are approved for adults and not for children. We conducted a test negative case-control study to assess the effectiveness of Measles Containing Vaccines (MCVs) against SARS-CoV-2 infectio
Externí odkaz:
https://doaj.org/article/3f41a446252440beaeeb1d91277e51f7
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 5, Pp 1103-1106 (2018)
Until recently, periodic Group A meningococcal meningitis outbreaks were a major public health problem in the sub-Saharan Africa. In 2001, the Meningitis Vaccine Project (MVP), a partnership between the World Health Organization (WHO) and PATH, a Sea
Externí odkaz:
https://doaj.org/article/0f6a6f018202449f82dfc05effb2b3fe
Publikováno v:
Expert Review of Vaccines, Vol 16, Iss 4, Pp 303-311 (2017)
Introduction: Rabies is a 100% fatal disease with significant disease burden in Asia and Africa but preventable with vaccines and immunoglobulins. There are very few WHO prequalified cell culture derived rabies vaccines available globally for use in
Externí odkaz:
https://doaj.org/article/b51a4d7eef94437a975e1fb476e6870d
Autor:
Ashish Bavdekar, Nandini Malshe, Latha Ravichandran, Amita Sapru, Anand Kawade, Sanjay Lalwani, Sonali Palkar, Neeta Hanumante, Bhagwat Gunale, Dhananjay Kapse, Amol Chaudhari, Tara Miller, Laura Saganic, Courtney Jarrahian, Sarah McGray, Darin Zehrung, Prasad S. Kulkarni
Publikováno v:
Contemporary Clinical Trials Communications, Vol 14, Iss , Pp - (2019)
Introduction: We conducted a randomized, observer-blind, non-inferiority, parallel-group clinical study of diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b conjugate (pentavalent) vaccination of infants in India. Goals w
Externí odkaz:
https://doaj.org/article/49d13e3a0b3f44c5bd46768819704fef